Ozempic Cost in California 2026: Insurance, Cash Price, and Savings Options

Ozempic List Price vs. What Californians Actually Pay

Novo Nordisk's list price for Ozempic has been reported at roughly $998 per month across U.S. markets, including California [1]. List price is set by the manufacturer and is not disclosed inside the FDA prescribing label, so treat any specific dollar figure, including this one, as a snapshot that needs to be checked against the current price at the time you fill a prescription rather than a fixed number.

Most insured patients pay less than list price because health plans negotiate rebates with manufacturers. The size of that gap is not public for any individual California plan, so avoid treating any specific percentage discount as a documented fact. What determines a patient's actual copay is formulary tier placement: preferred-brand tiers typically carry lower copays than non-preferred tiers, and some plans require a documented trial of metformin or another first-line therapy before approving Ozempic (step therapy).

Uninsured Californians face something close to the full list price unless they use a savings program. Pharmacy discount trackers such as GoodRx occasionally show lower cash prices at independent pharmacies, but the savings compared to list price are usually modest, on the order of a few percent, not the deep discounts available through insurance or manufacturer assistance.

Medi-Cal Coverage for Ozempic in California

Medi-Cal, California's Medicaid program, covers Ozempic for enrollees with a confirmed type 2 diabetes diagnosis, subject to prior authorization through Medi-Cal Rx.

Prior authorization criteria for GLP-1 medications under Medi-Cal typically involve documentation of glycemic control (commonly an elevated HbA1c) and a trial of first-line oral therapy such as metformin unless it is contraindicated. These criteria and the associated turnaround times change periodically, so a prescriber submitting a Treatment Authorization Request should confirm the current criteria and processing timeline directly with Medi-Cal Rx rather than relying on a fixed number from this or any other article.

One point that does not change from year to year: Medi-Cal does not cover Ozempic for weight management alone, because the FDA-approved indication for the Ozempic label is glycemic control in type 2 diabetes [1]. Patients seeking GLP-1 therapy for obesity fall under the separate Wegovy label (semaglutide 2.4 mg), which has its own formulary rules under Medi-Cal managed care.

Commercial Insurance Coverage Across California Plans

Major California commercial insurers, including Kaiser Permanente, Blue Shield of California, Anthem Blue Cross, Health Net, and Cigna, generally include semaglutide on their formularies for type 2 diabetes, but tier placement and prior authorization requirements vary by plan and change over time. The most reliable way to know what you will pay is to call the member services number on your insurance card and ask directly about tier placement, prior authorization, and step therapy requirements for Ozempic.

When a plan prefers an alternative GLP-1 medication such as dulaglutide (Trulicity) and a prescriber believes Ozempic is clinically preferable for a specific patient, the SUSTAIN-7 trial is the relevant published evidence for a formulary exception request. In that randomized, open-label phase 3b trial (N = 1,201), semaglutide produced greater reductions in HbA1c than dulaglutide over 40 weeks at matched dose-comparison pairs (0.5 mg semaglutide vs. 0.75 mg dulaglutide, and 1.0 mg semaglutide vs. 1.5 mg dulaglutide), with semaglutide also associated with greater weight loss [2]. Editors and prescribers citing exact percentage figures from this trial should pull them directly from the published paper rather than from secondhand summaries, since figures can be transcribed inconsistently.

Covered California marketplace plans generally cover Ozempic for type 2 diabetes with prior authorization. Cost-sharing reduction subsidies can lower copays for lower-income enrollees, but the exact copay depends on the specific plan and the enrollee's income tier, so treat any specific dollar figure as illustrative rather than guaranteed.

The Novo Nordisk Savings Card in California

Novo Nordisk has offered an Ozempic savings card to commercially insured patients that reduces out-of-pocket cost per fill, up to a stated maximum benefit. Because manufacturer savings programs change their terms, maximum benefit, and duration limits without much notice, confirm the current terms directly at Ozempic.com or by calling Novo Nordisk before counting on a specific number.

What is stable: patients covered by Medi-Cal, Medicare Part D, Tricare, or VA benefits are categorically ineligible for manufacturer copay cards, because these programs are restricted to commercially insured patients. What is not stable: the exact discount amount, the maximum number of months covered, and whether a specific employer plan uses a copay accumulator program that prevents the card's payment from counting toward the deductible or out-of-pocket maximum. If your plan uses an accumulator, ask your benefits administrator directly, since this can create an unexpected cost gap later in the plan year.

Compounded Semaglutide in California: Legal Status and Pricing

Compounded semaglutide is available in California through state-licensed 503A compounding pharmacies, which prepare patient-specific prescriptions when a prescriber determines the commercially manufactured product is not appropriate for that patient. Federal law (Section 503A of the Food, Drug, and Cosmetic Act) permits this type of compounding for individual patients with a valid prescription [3]. The FDA has also published guidance and safety communications specifically addressing semaglutide compounding and the risks of counterfeit or improperly sourced product, which is worth reading before starting compounded therapy [4].

Reported pricing for compounded semaglutide in California commonly falls somewhere between $150 and $300 per month, well below brand Ozempic, but pricing varies by pharmacy, dose, and formulation, and this article cannot verify any single pharmacy's current price. Confirm pricing directly with a specific California-licensed pharmacy.

One distinction matters regardless of the calendar year: 503A compounding for an individual patient with a valid prescription is generally lawful independent of drug shortage status, while larger-scale 503B outsourcing-facility compounding of semaglutide has depended on semaglutide's status on the FDA's drug shortage list. That status has changed before and can change again, so confirm current shortage status and confirm that any pharmacy you use holds current California Board of Pharmacy licensure and complies with USP 797 sterile compounding standards, including certificates of analysis for potency and sterility [4].

Telehealth Access to Ozempic in California

California permits telehealth prescribing of Ozempic without requiring an in-person visit first, provided the prescribing clinician holds an active California license and follows the same standard of care expected of in-person prescribing. That generally means a metabolic health assessment, review of relevant labs (HbA1c, fasting glucose, kidney function), and screening for contraindications, including a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, which are contraindications on the Ozempic label [1].

Reported consultation fees for telehealth semaglutide evaluation vary by platform, and some platforms bundle the consultation fee with compounded medication while others charge separately. Confirm total cost, including any recurring consultation or membership fees, before starting.

Reducing Out-of-Pocket Cost: Practical Options

The right approach depends on insurance status.

Commercially insured patients should call the number on their insurance card to confirm formulary tier placement before assuming a price. If Ozempic sits on a non-preferred tier, a prescriber can request a formulary exception, and SUSTAIN-7 data is the relevant clinical evidence to cite if the plan prefers a different GLP-1 medication [2]. A manufacturer savings card, if the patient qualifies, can reduce cost during the exception review period.

Medi-Cal enrollees with type 2 diabetes should confirm with their prescriber that the prior authorization request includes current HbA1c results and documentation of a metformin trial or contraindication, since incomplete documentation is a common reason for delay or denial. Denials can be appealed through the Medi-Cal fair hearing process.

Uninsured patients have several options worth investigating, each with its own eligibility rules that change periodically:

1. The Novo Nordisk Patient Assistance Program, which has historically provided free medication to patients below an income threshold tied to the federal poverty level. Confirm the current-year dollar threshold directly with the program, since federal poverty level figures are updated annually.
2. Compounded semaglutide through a California-licensed 503A pharmacy, at a reported cost well below brand pricing.
3. Federally Qualified Health Centers, which can access 340B drug pricing. California has more than 100 FQHCs; patients receiving care there may be able to access GLP-1 medications at reduced cost, though this depends on the specific center's formulary and pricing.

Ozempic Dose Titration and Cost Implications

Ozempic uses a fixed-dose pen. The standard approach starts at 0.25 mg weekly for four weeks (an initiation dose, not a therapeutic one), increases to 0.5 mg weekly for at least four weeks, and may increase further to 1.0 mg and then 2.0 mg based on glycemic response and tolerability [1]. Each pen supplies four weeks of medication regardless of dose, so the list price for a month of therapy is generally the same whether the patient is on a lower or higher dose pen.

For compounded semaglutide, pricing more often scales with dose, so a monthly supply at a higher dose can cost more than the same duration at a starting dose. Confirm dose-based pricing directly with the compounding pharmacy.

SUSTAIN-7 also demonstrated a dose-response relationship within the semaglutide arms, with the higher studied dose associated with greater average HbA1c reduction and weight loss than the lower studied dose over 40 weeks [2]. Clinicians and patients weigh that incremental benefit against tolerability, since gastrointestinal side effects are the most common reason patients do not escalate beyond a given dose. Anyone citing exact percentage or weight figures from this trial should verify them against the published paper rather than a secondhand summary, since we found an internal inconsistency in the prior version of this page and removed the unverified numbers rather than repeat the error.

California-Specific Pharmacy Pricing Variation

Because Ozempic's list price is set by the manufacturer, cash-pay prices at major chain pharmacies in California tend to cluster in a relatively narrow band, with independent pharmacies and membership-based pharmacies sometimes posting modestly lower prices due to different wholesaler contracts. These are the kinds of figures that shift month to month and pharmacy to pharmacy, so a discount price comparison tool checked at the time of filling is more reliable than any number printed here.

Cost Plus Drugs, the low-markup pharmacy platform, has generally excluded brand-name drugs like Ozempic from its transparent pricing model, since that model is built around generics; confirm current availability directly if this is relevant to your search.

California's drug pricing transparency law (SB 17) requires manufacturers to give advance notice before certain large price increases, which is part of why sudden Ozempic list price jumps are rare and typically get public attention when they happen. For the exact current notice threshold and timeline, consult the statute or the California Office of Statewide Health Planning and Development rather than this summary.

What Happens If Your California Insurance Denies Ozempic

California gives patients a specific appeal right when a health plan denies a prescribed medication. Under California Health and Safety Code Section 1368.01, patients can request an Independent Medical Review through the Department of Managed Health Care at no cost, and an external physician reviewer assesses whether the denial was medically appropriate. Expedited review is available for urgent cases, such as a patient with poorly controlled diabetes, when a prescriber attests to the urgency.

We are not including a specific statistic on how often these reviews favor the patient, because the figure in the prior version of this page was not tied to a verifiable current source; if that statistic matters to your decision, request current outcome data directly from the Department of Managed Health Care.

Documentation that generally strengthens an appeal includes records of prior medication trials and failures, an HbA1c trend showing inadequate control, relevant cardiovascular risk factors, and a specialist letter supporting medical necessity. On the cardiovascular point: the SELECT trial found that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20 percent (hazard ratio 0.80) compared with placebo in adults with overweight or obesity and established cardiovascular disease but without diabetes (N = 17,604) [5]. This trial used the Wegovy dose and studied a different population than people prescribed Ozempic for type 2 diabetes, so it should be presented in an appeal as background on semaglutide's cardiovascular profile rather than as direct evidence about the Ozempic-labeled population.

Verification Checklist: What You Can Trust Today vs. What You Must Recheck

Coverage and pricing information for a drug like Ozempic mixes two very different kinds of facts. Federal approvals and published trial results are stable and rarely change without notice. Insurer, state program, and cash-price details change often, sometimes month to month. Use this checklist to know which is which before you act on anything in this article or elsewhere.

Stable facts (safe to rely on without rechecking, though it's still worth confirming you have the current label version):

• Ozempic's FDA-approved indication is glycemic control in type 2 diabetes; it is not FDA-approved for weight loss [1].
• Ozempic's dosing schedule (0.25 mg to 2.0 mg, once weekly, titrated over time) and its labeled contraindications, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome [1].
• Federal law permits 503A patient-specific compounding by licensed pharmacies with a valid prescription [3].
• SUSTAIN-7 and SELECT are published, peer-reviewed trials with results available in the original papers [2] [5].
• California law permits telehealth prescribing of a controlled therapeutic relationship without a prior in-person visit, and gives patients the right to an Independent Medical Review after a health plan denial.

Date-sensitive facts (verify at the time of the decision, not from this article):

• Ozempic's current list price and current cash price at a specific pharmacy.
• Your specific insurance plan's formulary tier, copay, and prior authorization or step therapy requirements. Call the number on your card.
• Medi-Cal Rx's current prior authorization criteria and processing timeline for GLP-1 medications.
• The Novo Nordisk savings card's current eligibility rules, discount amount, and duration limit, and whether your employer plan uses a copay accumulator.
• Semaglutide's current status on the FDA drug shortage list, which affects the legality of 503B (not 503A) compounding.
• A specific compounding pharmacy's current pricing, licensure status, and quality documentation.
• The current federal poverty level dollar thresholds used by patient assistance programs.
• The status of any pending state legislation affecting copay accumulators or drug pricing.

If a number in this article and a number you get directly from a plan, pharmacy, or state agency disagree, trust the source you checked directly. Prices and coverage rules in this space change faster than most editorial content can track.